What are the indications for initiating anticoagulation therapy in a patient with severe mitral stenosis?

Indications to Start Anticoagulation in Severe Mitral Stenosis

Anticoagulation is mandatory in severe mitral stenosis with atrial fibrillation, prior embolic events, or left atrial thrombus, and should be strongly considered in asymptomatic patients with left atrial enlargement ≥55 mm or spontaneous echo contrast.

Absolute Indications (Class I - Must Anticoagulate)

Initiate anticoagulation immediately in these scenarios:

• Atrial fibrillation present (regardless of CHA2DS2-VASc score) 1, 2

  • Target INR 2.5-3.5 with warfarin 2
  • DOACs are contraindicated in moderate-to-severe mitral stenosis 3

• Prior embolic event - even if currently in sinus rhythm 1

• Left atrial thrombus documented on echocardiography 1

Strong Considerations (Class IIb - Should Consider)

Anticoagulation may be considered in asymptomatic severe MS patients with:

• Left atrial dimension ≥55 mm by echocardiography 1

• Spontaneous echo contrast in enlarged left atrium on TEE 1, 2

The rationale: These findings indicate a prothrombotic left atrial environment with embolic risk approaching 1.5-6 per 100 patient-years 2. Recent evidence demonstrates hypercoagulable states in severe MS patients with left atrial appendage inactivity, even in sinus rhythm, with significantly elevated procoagulant markers comparable to atrial fibrillation 4.

Critical Anticoagulation Details

Choice of anticoagulant:

• Warfarin is the only recommended agent for mitral stenosis 3
• Target INR 2.5-3.5 for patients with atrial fibrillation 2
• Target INR 2.0-3.0 may be acceptable in Asian populations based on recent data showing comparable net clinical events with lower bleeding risk 5
• Never use DOACs - they are explicitly excluded in moderate-to-severe mitral stenosis due to lack of safety/efficacy data and increased risk demonstrated in trials 3, 6

Common Pitfalls to Avoid

1. Do not apply CHA2DS2-VASc scoring to mitral stenosis patients - anticoagulation is indicated regardless of score when AF is present 1, 7

2. Do not delay anticoagulation in patients planning percutaneous mitral commissurotomy (PMC) - they require at least 4 weeks of effective anticoagulation pre-procedure if high embolic risk features present 2

3. Do not assume sinus rhythm is protective - 20% of thromboembolic events occur as the initial presentation, and embolic risk remains elevated even without AF when left atrial abnormalities exist 2

4. Recognize paroxysmal AF - 56% of MS patients in apparent sinus rhythm have transient atrial arrhythmias on Holter monitoring, with 14% experiencing embolic events 2

Clinical Decision Algorithm

Step 1: Confirm severe MS (MVA ≤1.0-1.5 cm²)

Step 2: Check for absolute indications:

• AF present? → Start warfarin (INR 2.5-3.5)
• Prior embolism? → Start warfarin
• LA thrombus? → Start warfarin

Step 3: If in sinus rhythm without above features, assess:

• LA diameter ≥55 mm? → Consider warfarin
• Spontaneous echo contrast on TEE? → Consider warfarin
• Both present? → Strongly favor anticoagulation

Step 4: Perform TEE if considering PMC or if high clinical suspicion for paroxysmal AF

The evidence strongly supports that mitral stenosis creates a unique prothrombotic milieu independent of traditional AF risk stratification, justifying a lower threshold for anticoagulation compared to other cardiac conditions 4, 7.